Holen Sie sich die Stockscreener-App
1.24
0.00%
0.00
Schlusskurs vom Vortag:
$1.24
Offen:
$1.23
24-Stunden-Volumen:
50,412
Relative Volume:
0.14
Marktkapitalisierung:
$70.15M
Einnahmen:
$3.67M
Nettoeinkommen (Verlust:
$-13.83M
KGV:
-4.4286
EPS:
-0.28
Netto-Cashflow:
$-10.79M
1W Leistung:
+8.77%
1M Leistung:
-8.82%
6M Leistung:
+106.67%
1J Leistung:
-7.46%
1-Tages-Spanne:
$1.2001
$1.26
1-Wochen-Bereich:
$1.04
$1.26
52-Wochen-Spanne:
$0.48
$1.66
Icecure Medical Ltd Stock (ICCM) Company Profile
Firmenname
Icecure Medical Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ICCM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
1.24 | 70.15M | 3.67M | -13.83M | -10.79M | -0.28 |
|
ABT
Abbott Laboratories
|
131.62 | 225.32B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
100.58 | 149.74B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
374.08 | 142.48B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
88.55 | 113.49B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
72.03 | 42.10B | 5.72B | 4.17B | 259.90M | 6.97 |
Icecure Medical Ltd Aktie (ICCM) Neueste Nachrichten
IceCure Medical Stock Dips Despite Positive ICESECRET Study Results - Zacks Investment Research
Genomic Differences Impact Real World Use of Elacestrant in Breast Cancer - Targeted Oncology
H.C. Wainwright maintains Buy on IceCure Medical with $2.50 target - Investing.com India
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2024 Earnings Call Transcript - Insider Monkey
H.C. Wainwright maintains Buy on IceCure Medical with $2.50 target By Investing.com - Investing.com South Africa
IceCure Medical Reports Growth and Awaits FDA Decision - TipRanks
IceCure Medical Ltd’s Earnings Call: Growth Amidst Challenges - TipRanks
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025 - PR Newswire
Earnings call transcript: Icecure Medical’s Q4 2024 sees growth in sales but wider losses By Investing.com - Investing.com South Africa
Earnings call transcript: Icecure Medical’s Q4 2024 sees growth in sales but wider losses - Investing.com
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America - StreetInsider.com
IceCure Reports 42% Growth: ProSense Sales Soar as FDA Breast Cancer Decision Nears - Stock Titan
Earnings Outlook For Icecure Medical - Benzinga
IceCure Medical aims to bring cold cancer treatment to Vietnam - Mugglehead Magazine
Cryoablation Breast Cancer Treatment - Clinical Oncology News
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate - The Malaysian Reserve
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Res - GuruFocus
IceCure reports high efficacy in kidney tumor cryoablation study By Investing.com - Investing.com South Africa
IceCure reports high efficacy in kidney tumor cryoablation study - Investing.com India
Breakthrough: New Kidney Cancer Study Shows 89% Success Rate with IceCure's Freezing Technology - Stock Titan
IceCure Medical Earnings: Cryoablation Pioneer Reports 2024 Results March 27 - Stock Titan
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer - The Malaysian Reserve
Targeting ESR1 Mutations in Breast Cancer With Novel Therapies - Targeted Oncology
IceCure stock tumbles after update on ProSense (ICCM:NASDAQ) - Seeking Alpha
IceCure Medical Ltd. Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense®? Cryoablation in Early-Stage Breast Cancer - Marketscreener.com
IceCure Medical Expects FDA Decision on ProSense After Q1 -March 20, 2025 at 09:20 am EDT - Marketscreener.com
IceCure nears FDA decision on breast cancer treatment - Investing.com
IceCure nears FDA decision on breast cancer treatment By Investing.com - Investing.com UK
IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference - PR Newswire
Breakthrough: IceCure's Breast Cancer Treatment Achieves 94% Complete Ablation Rate in New Studies - Stock Titan
Critical Survey: IceCure Medical (NASDAQ:ICCM) and Medifocus (OTCMKTS:MDFZF) - Defense World
IceCure secures patent for cryogenic pump in China By Investing.com - Investing.com Australia
IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology - Quantisnow
IceCure Gets Notice of Allowance from China's Intellectual Property Regulator -March 17, 2025 at 09:07 am EDT - MarketScreener
IceCure secures patent for cryogenic pump in China - Investing.com
Market Sentiment Around Loss-Making IceCure Medical Ltd (NASDAQ:ICCM) - Simply Wall St
IceCure's ProSense® Cryoablation Featured in Six Studies Present - GuruFocus.com
Breast Cancer Patients Report Higher Satisfaction with Cryoablation - Imaging Technology News
IceCure Medical (NASDAQ:ICCM) Trading Down 4.4% – Time to Sell? - Defense World
Clinical Study: ProSense Shows Superior Patient Satisfaction vs Traditional Breast Cancer Therapy - StockTitan
Breast Cancer Patients who Underwent IceCure's ProSense® Cryoablation in Japan Reported Significantly Higher Satisfaction than Patients who Underwent Standard of Care Surgery - The Malaysian Reserve
IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade - MSN
IceCure seeks Israeli regulatory approval for XSense cryoablation system - Yahoo
IceCure seeks Israel approval for XSense cryoablation system By Investing.com - Investing.com Australia
IceCure Medical Ltd. Submits Filing for Regulatory Approval of Its Next-Generation XSense? Cryoablation System in Israel - Marketscreener.com
IceCure seeks Israel approval for XSense cryoablation system - Investing.com
IceCure Submits Filing for Regulatory Approval of its Next-Generation XSense™ Cryoablation System in Israel - PR Newswire
Finanzdaten der Icecure Medical Ltd-Aktie (ICCM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.76%
1.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):